biostudies-literatureMungle TIndian Council of Medical ResearchWellcome Trust3499-3508https://www.ebi.ac.uk/biostudies/studies/S-EPMC9939102biostudies-literatureUnknown12(3)<h4>Background</h4>To evaluate the treatment cost and cost effectiveness of a risk-stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India.<h4>Methods</h4>The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B-cell precursor ALL, and T-ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability-adjusted life years.<h4>Results</h4>One hundred and forty five patients, SR (50), IR (36), HR (39), and T-ALL (20) were analyzed. Median cost of the entire treatmeCancer medicineComparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.PMC993910279/159/2015/NCD‐IIGhara NGhosh DSaha VMungle TDas NDas PPal SArora RSGogoi MPBhakta NKrishnan SfalseComparative treatment costs of risk-stratified therapy for childhood acute lymphoblastic leukemia in India.<h4>Background</h4>To evaluate the treatment cost and cost effectiveness of a risk-stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India.<h4>Methods</h4>The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B-cell precursor ALL, and T-ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability-adjusted life years.<h4>Results</h4>One hundred and forty five patients, SR (50), IR (36), HR (39), and T-ALL (20) were analyzed. Median cost of the entire treatme2023-01-01T00:00:00Z2023 Feb2025-08-18T09:53:19.536Z2025-04-05T23:49:59.374ZS-EPMC99391023681212010.1002/cam4.5140